Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value

von Zhou, Qing, Wu, Yi-Long
Veröffentlicht in J Glob Oncol (2016)

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review

von Su, Shan, Wu, Yi-Long
Veröffentlicht in J Hematol Oncol (2017)

Immunotherapy in the Asiatic population: any differences from Caucasian population?

von Peng, Lunxi, Wu, Yi-Long
Veröffentlicht in J Thorac Dis (2018)

Surgery in oligometastatic NSCLC patients in the targeted therapy era

von Zhang, Qi, Wu, Yi-Long
Veröffentlicht in Lung Cancer Manag (2016)

Novel agents and strategies for overcoming EGFR TKIs resistance

von Niu, Fei-Yu, Wu, Yi-Long
Veröffentlicht 2014

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib

von Niu, Fei-Yu, Wu, Yi-Long
Veröffentlicht in Onco Targets Ther (2015)

Insight into early-phase trials for lung cancer in the United States

von Yang, Jin-Ji, Wu, Yi-Long
Veröffentlicht in Chin J Cancer (2015)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 bloc...

von Wu, Si-Pei, Wu, Yi-Long
Veröffentlicht in J Immunother Cancer (2015)

CSCO joins ESMO Open—Cancer Horizons

von Zielinski, Christoph C, Wu, Yi-Long
Veröffentlicht in ESMO Open (2016)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

von Gou, Lan-Ying, Wu, Yi-Long
Veröffentlicht in Lung Cancer (Auckl) (2014)

Misuse of Pirated Drugs: Why China? What Is Next?

von Sun, Hui-wen, Wu, Yi-Long
Veröffentlicht in J Glob Oncol (2016)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

von Liu, Si-Yang, Wu, Yi-Long
Veröffentlicht in J Hematol Oncol (2017)

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

von Ke, E-E, Wu, Yi-Long
Veröffentlicht in Ther Adv Respir Dis (2016)

Adjuvant TKIs: still an optimal choice

von Liu, Si-Yang, Wu, Yi-Long
Veröffentlicht in J Thorac Dis (2018)

Personalized adjuvant treatment: go through the past to the future

von Liu, Si-Yang, Wu, Yi-Long
Veröffentlicht in J Thorac Dis (2019)

Biomarker for personalized immunotherapy

von Liu, Si-Yang, Wu, Yi-Long
Veröffentlicht in Transl Lung Cancer Res (2019)

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial P...

von Tu, Hai-Yan, Wu, Yi-Long
Veröffentlicht in Onco Targets Ther (2020)

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis

von Xu, Chongrui, Zhou, Qing, Wu, Yi-long
Veröffentlicht 2012

Special issue on personalized therapy in lung cancer

von Zhang, Na, Zhong, Wen-Zhao, Wu, Yi-Long
Veröffentlicht in Transl Lung Cancer Res (2014)

Emerging challenges of advanced squamous cell lung cancer

von Zhang, Yi-Chen, Zhou, Qing, Wu, Yi-Long
Veröffentlicht in ESMO Open (2017)